Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 237

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour

The Worldwide Atosiban versus Beta‐agonists Study Group Participants are listed in·2001·BJOG: An International Journal of Obstetrics & Gynaecology

Abstract

Objective To compare the effectiveness and safety of the oxytocin antagonist atosiban with conventional beta‐adrenergic agonist (beta‐agonist) therapy in the treatment of preterm labour. Design Three multinational, multicentre, double‐blind, randomised, controlled trials. Setting Hospitals in Australia, Canada, Czech Republic, Denmark, France, Israel, Sweden, and the UK. Population Women diagnosed with preterm labour at 23–33 completed weeks of gestation. Methods Seven hundred and forty‐two women were randomised; 733 received atosiban (n=363; intravenous (iv) bolus dose of 6.75 mg, then 300 μg/minute iv. for 3h and 100 μg/min iv thereafter) or beta‐agonist (n=379; ritodrine, salbutamol or terbutaline iv; dose titrated) for at least 18h and up to 48 hours. Uterine contraction rate, cervical dilatation and effacement were used to assess progression of labour. An all patients treated analysis, using the Cochran‐Mantel‐Haenszel test, was performed. Main outcome measures Tocolytic effectiveness was assessed in terms of the number of women undelivered after 48 hours and seven days. Safety was assessed in terms of maternal side effects and neonatal morbidity. Results There were no significant differences between atosiban and β‐agonists in delaying delivery for 48h (88.1% vs 88.9%; P=0.99) or seven days (79.7% versus 77.6%; P=0.28). Tocolytic effectiveness was also similar in terms of mean [SD] gestational age at delivery (35.8 [3.9] weeks vs 35.5 [4.1] weeks) and mean [SD] birthweight (2491 [813] g versus 2461 [831] g). Maternal side effects, particularly cardiovascular adverse events (8.3% vs 81.2%, P < 0.001), were reported more frequently in women given β‐agonists, resulting in more treatment discontinuations due to side effects (1.1% vs 15.4%, P=0.0001). No statistical differences in neonatal/infant outcomes were observed with either study medication. Conclusions In the largest study of tocolytic therapy to date, atosiban was comparable in clinical effectiveness to conventional beta‐agonist therapy, but was associated with fewer maternal cardiovascular side effects. We conclude that atosiban has clinical advantages over current tocolytic therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1471-0528.2001.00043.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 237

Metadata

Authors
The Worldwide Atosiban versus Beta‐agonists Study Group Participants are listed in
Venue
BJOG: An International Journal of Obstetrics & Gynaecology
Publisher
Wiley
Published
2001-02
Volume
108
Issue
2
Pages
133-142
ISSN
  • 0306-5456 (ISSN-L)
  • 1470-0328
  • 1471-0528
OpenAlex
W1876794067
Cited by
237
References
2
FWCI
14.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. https://app.cochat.ai/papers/10.1111/j.1471-0528.2001.00043.x
The paper
The Worldwide Atosiban versus Beta‐agonists Study Group Participants are listed in. (2001). Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/j.1471-0528.2001.00043.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.